Enveric Biosciences Inc. has expanded its collaboration with TOTEC Pharma through a trademark license agreement. Enveric's subsidiary, Akos Biosciences, has licensed its US trademark portfolio for RCANN™ and an RCANN™ design to TOTEC Pharma, which is working to commercialize Enveric's patented cannabinoid crème technology for the treatment of radiation dermatitis. The agreement also includes an option for TOTEC to purchase the RCANN trademark portfolio in the future, contingent on meeting certain development and commercialization milestones. This partnership aims to advance the cannabinoid technology towards commercialization and may generate significant milestone payments and royalties for Enveric.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260129235695) on January 29, 2026, and is solely responsible for the information contained therein.